"Omalizumab" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
An anti-IgE, recombinant, humanized monoclonal antibody which specifically binds to the C epsilon3 domain of IMMUNOGLOBULIN E, the site of high-affinity IgE receptor binding. It inhibits the binding of IgE to MAST CELLS and BASOPHILS to reduce the severity of the allergic response and is used in the management of persistent allergic ASTHMA.
Descriptor ID |
D000069444
|
MeSH Number(s) |
D12.776.124.486.485.114.071.500 D12.776.124.486.485.114.224.060.844 D12.776.124.790.651.114.071.500 D12.776.124.790.651.114.224.060.844 D12.776.377.715.548.114.071.500 D12.776.377.715.548.114.224.200.844
|
Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Omalizumab".
- Chemicals and Drugs [D]
- Amino Acids, Peptides, and Proteins [D12]
- Proteins [D12.776]
- Blood Proteins [D12.776.124]
- Immunoproteins [D12.776.124.486]
- Immunoglobulins [D12.776.124.486.485]
- Antibodies [D12.776.124.486.485.114]
- Antibodies, Anti-Idiotypic [D12.776.124.486.485.114.071]
- Omalizumab [D12.776.124.486.485.114.071.500]
- Antibodies, Monoclonal [D12.776.124.486.485.114.224]
- Antibodies, Monoclonal, Humanized [D12.776.124.486.485.114.224.060]
- Omalizumab [D12.776.124.486.485.114.224.060.844]
- Serum Globulins [D12.776.124.790]
- Immunoglobulins [D12.776.124.790.651]
- Antibodies [D12.776.124.790.651.114]
- Antibodies, Anti-Idiotypic [D12.776.124.790.651.114.071]
- Omalizumab [D12.776.124.790.651.114.071.500]
- Antibodies, Monoclonal [D12.776.124.790.651.114.224]
- Antibodies, Monoclonal, Humanized [D12.776.124.790.651.114.224.060]
- Omalizumab [D12.776.124.790.651.114.224.060.844]
- Globulins [D12.776.377]
- Serum Globulins [D12.776.377.715]
- Immunoglobulins [D12.776.377.715.548]
- Antibodies [D12.776.377.715.548.114]
- Antibodies, Anti-Idiotypic [D12.776.377.715.548.114.071]
- Omalizumab [D12.776.377.715.548.114.071.500]
- Antibodies, Monoclonal [D12.776.377.715.548.114.224]
- Antibodies, Monoclonal, Humanized [D12.776.377.715.548.114.224.200]
- Omalizumab [D12.776.377.715.548.114.224.200.844]
Below are MeSH descriptors whose meaning is more specific than "Omalizumab".
This graph shows the total number of publications written about "Omalizumab" by people in this website by year, and whether "Omalizumab" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
Year | Major Topic | Minor Topic | Total |
---|
2006 | 0 | 1 | 1 |
2008 | 0 | 1 | 1 |
2011 | 0 | 1 | 1 |
2012 | 0 | 1 | 1 |
2013 | 0 | 1 | 1 |
2014 | 0 | 1 | 1 |
2015 | 1 | 1 | 2 |
2017 | 1 | 0 | 1 |
2018 | 1 | 0 | 1 |
2019 | 3 | 0 | 3 |
2020 | 0 | 4 | 4 |
2021 | 0 | 1 | 1 |
2022 | 0 | 1 | 1 |
2023 | 0 | 1 | 1 |
2024 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Omalizumab" by people in Profiles.
-
Effectiveness of omalizumab across different dosing regimens in patients with moderate-to-severe allergic asthma. Respir Med. 2024 Mar; 223:107537.
-
Influence of baseline bronchodilator reversibility and blood eosinophils on lung function in patients with asthma following omalizumab. J Allergy Clin Immunol Pract. 2024 02; 12(2):512-514.e2.
-
Successful Elosulfase Alfa Desensitization Protocol in a Patient With Morquio A Syndrome. Pediatrics. 2022 02 01; 149(2).
-
Omalizumab in Asthma with Fixed Airway Obstruction: Post Hoc Analysis of EXTRA. J Allergy Clin Immunol Pract. 2022 01; 10(1):222-228.
-
Preventing asthma in high risk kids (PARK) with omalizumab: Design, rationale, methods, lessons learned and adaptation. Contemp Clin Trials. 2021 01; 100:106228.
-
Efficacy and safety of treatment with biologicals (benralizumab, dupilumab and omalizumab) for severe allergic asthma: A systematic review for the EAACI Guidelines - recommendations on the use of biologicals in severe asthma. Allergy. 2020 05; 75(5):1043-1057.
-
Efficacy and safety of treatment with biologicals (benralizumab, dupilumab, mepolizumab, omalizumab and reslizumab) for severe eosinophilic asthma. A systematic review for the EAACI Guidelines - recommendations on the use of biologicals in severe asthma. Allergy. 2020 05; 75(5):1023-1042.
-
Determinants of lung function improvement with omalizumab in adults with allergic asthma. J Allergy Clin Immunol Pract. 2020 06; 8(6):2068-2070.
-
Omalizumab Treatment Patterns Among Patients with Asthma in the US Medicare Population. J Allergy Clin Immunol Pract. 2020 02; 8(2):507-515.e10.
-
Controversies in Allergy: Should Severe Asthma with Eosinophilic Phenotype Always Be Treated with Anti-IL-5 Therapies. J Allergy Clin Immunol Pract. 2019 May - Jun; 7(5):1430-1436.